18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
Status:
Recruiting
Trial end date:
2023-02-15
Target enrollment:
Participant gender:
Summary
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during
an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed
tomography (PET/CT) in patients with brain cancer or cancer that has spread to the brain
(brain metastases). A PET/CT scan is an imaging test that uses a small amount of radioactive
tracer (given through the vein) to take detailed pictures of areas inside the body where the
tracer is taken up. 18F-FMAU may also help find the cancer and how far the disease has
spread. Magnetic resonance imaging (MRI) is a type of imaging test used to diagnose brain
tumors. 18F-FMAU PET/CT in addition to MRI may make the finding and diagnosing of brain tumor
easier.